Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
|
|
- Elizabeth Stewart
- 5 years ago
- Views:
Transcription
1 1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation of our study, and for allowing us to send you a revised version of our article! Below we address the comments raised by the committee and the reviewers and outline the related changes made to the paper. Overall, we agree with the committee s concern on making claims about treatment guidelines. We should leave that to those who are responsible for that process. The main message of our study is, in fact, to question the use of observational studies as supportive evidence against reducing systolic blood pressure to below 130 mm Hg. The word evidence was used by the authors of the 2013 guidelines from the European Societies of Cardiology and Hypertension. But we believe that it is necessary to use all available information from real life observational studies as one of several sources for defining best practice. We have tried to be cautious about drawing conclusions about treatment, which has been noted by reviewer 2. We have followed your recommendation to further tone down causal inference in our conclusions and made changes in the manuscript that further emphasize association rather than causal effect, as described in our reply. We believe that the ongoing debate about blood pressure in diabetes would benefit from this new data. As this is by far the largest study on the topic, our results will greatly expand available data for discussions in future revisions of treatment guidelines. Apart from this specific value we believe that there is a broad interest in the results since decisions on how to treat blood pressure in patients with diabetes is an important part of daily work for physicians in primary care and internal medicine. We hope that we have answered all comments and made the required changes and that you will find our study suitable for your journal. We would like to inform you that an abstract on our study have been accepted for presentation at the 52nd European Association of the Study of Diabetes Annual Meeting in Münich, September 15. The following day, one of the main sessions is entitled Blood pressure in diabetes How low to go. It is not unlikely that our study will receive attention in this context. We therefore ask whether this presentation is in line with your peer review process? If not, we will of course adapt to any embargo policies that The British Medical Journal might have. Or would it perhaps be possible to coordinate a potential publishing of the article with this major international conference? Yours sincerely, Samuel Adamsson Eryd On behalf of the authors
2 2 Comments from the committee The committee was interested in the topic of your research. We thought this was a large and well conducted study of the impact of different blood pressure cut-offs on various cardiovascular outcomes. The following concerns were mentioned: The committee shared the reviewers concerns. The group with the lowest blood pressure had the highest total mortality so those who died of non-cvd causes (the majority of deaths) were not available to have a CVD event. Reply: Competing risks certainly affects the crude number of observed events as patients who die can t contribute with other events beyond that. In the analysis we have treated death as a censoring event which essentially means that the Kaplan-Meier estimates of survival curves for the other events represents the curves we would see in the absence of deaths. This relies on an assumption of censoring being non informative which may not be entirely fulfilled in some cases as patients who for example die from CV related causes (fatal MI, CHD and CVD) may have an elevated risk of nonfatal CV events compared to other patients had they not died. In the present study, only a relatively limited number of patients die from CV related causes and even if this would constitute an informative censoring this would have limited impact on the results. The assumption that censoring due to death from causes other than CV related is non-informative may have a better chance of holding, and this constitutes the majority of censorings due to death. While the impact of informative censoring could partly be explored using inverse probability of censoring weighting, this both adds considerable complexity to the already complex analysis and would need data on predictors of censoring to be available shortly prior to censoring for all patients and also that we could correctly model the censoring mechanism. We believe that this would not add any further value to the paper. The committee thought it was poorly described in places, and comparison of patients without and with pre-existing disease hard to follow, with the unselected group described only in the supplementary tables. Reply: The pre-defined objective was to study patients who were without previous cardiovascular disease. We realized, however, that readers might be interested in making comparisons between those with and without previous disease, and therefore added a supplemental table describing the baseline characteristics of a population including individuals with previous disease. The additional table was intentionally not placed in the main manuscript since we thought it might distract focus from the actual population being studied, namely those who were without previous diseases. To clarify the description of the study population we have changed the title of Table 1 from Baseline characteristics of subjects with various systolic blood pressure levels. Individuals with previous disease excluded and instead write Baseline characteristics of subjects with various systolic blood pressure levels. Inclusion criteria of the study population is well described in the text and figure 1. We have also changed the title of Table S1 from study population including individuals with previous disease to total population including those with previous disease. If the BMJ desires, we can easily insert this additional table in the main manuscript to facilitate comparison between the study population with and without those with previous disease.
3 3 The committee thought you might consider to tone down causal inference (conclusions in the abstract and the "what this adds") Reply: Thank you for your suggestion! We have modified our conclusions in an attempt to tone down causal inference. Previously we wrote: Lower systolic blood pressure than currently recommended can be beneficial for patients with type 2 diabetes. The association between low blood pressure and increased mortality is conceivably due to concomitant disease rather than antihypertensive treatment. Now we write: Lower systolic blood pressure than currently recommended is associated with significantly lower risk of cardiovascular events in patients with type 2 diabetes. The association between low blood pressure and increased mortality may be due to concomitant disease rather than antihypertensive treatment. Please word the objectives of the paper in the abstract more clearly. Reply: The objectives in the abstract have been modified to make it clearer: Objectives To compare the risk associated with a systolic blood pressure that meets current recommendations (i.e. below 140 mmhg) with the risk of lower levels in patients who have type 2 diabetes and no previous cardiovascular disease. The committee was slightly confused about the actual question being studied. You talk about the effect of BP treatment but in effect you are looking at the association of BP levels and outcomes. Reply: The main reason for conducting this study was a concern about recently changed treatment recommendations allowing a higher blood pressure. These changes are to a great extent based on findings from observational studies where conclusions have been drawn about treatment to low levels and associations have been referred to as evidence for a cause - effect relationship. The observational design of our study does not allow conclusions about blood pressure levels as an effect of antihypertensive treatment. We are only able to estimate the risk associated with having a certain systolic blood pressure, regardless of this being due to treatment or any other factor. As we have stated in the discussions section, page 17: We believe that caution should be exercised when using observational studies to draw conclusions about recommended treatment goals for blood pressure among high-risk patients. Uncertainty will always exist as to whether blood pressure is an effect of treatment or a disease that cannot be controlled for. As a consequence, we are cautious in our conclusions when we state that Lower systolic blood pressure than currently recommended is associated with significantly lower risk of cardiovascular events in patients with type 2 diabetes. We deliberately avoid to state whether these lower blood pressure levels should be achieved by antihypertensive treatment or other means. Since the recommended blood pressure targets were changed from below 130 mmhg to below 140 mmhg, we predefined the group with blood pressure between 130 and 140 mmhg as reference group when comparing the risk of having other blood pressure levels. In summary, our main objective was to compare the risk with a systolic blood pressure below 140 mmhg with the risk of lower levels. Our conclusion was that having lower levels is associated with significantly lower risk of cardiovascular events. We leave it to professional societies to decide whether the results will influence any revisions of current guidelines. We believe, however, that our study adds new and important information to the ongoing debate about the J- curve phenomenon and blood pressure targets.
4 4 You state that your hypothesis is that "the J-curve phenomenon (association of BP and bad outcomes in DM patients) is due to concomitant comorbidities, we examined the predictive value of systolic blood pressure at baseline on future cardiovascular events among patients with type 2 diabetes after excluding those with a history of cardiovascular or other major disease. In addition, we employed several methods to minimize uncontrolled confounding by other risk factors." To test the hypothesis you take a cohort without significant CV comorbidities at baseline, group them according to baseline BP levels and then see if overtime they develop bad outcomes. You conclude that the hypothesis is correct because you do not observe the J-curve phenomenon. In this group the association of BP and bad outcomes is linear. The aim was to compare the risk associated with a systolic blood pressure that meets current recommendations with the risk of lower levels in patients who have type 2 diabetes and no previous cardiovascular disease. In our opinion, it is more difficult to interpret the results when you make claims about treatment guidelines because we do not know to what extent the patients were being treated to meet a guideline goal. Did guidelines change during the time patients in the analysis were entered in the database ( )? Were patients being aggressively managed to meet the goal at baseline (i.e. entry into the database?) Did treatment intensity change over time for each patient? Reply: It is true that we are unable to know to what extent the patients were treated to meet the guideline goal and it is possible that some patients were aggressively managed to meet the goal at baseline. However, as we state in the discussion section: we included only patients with diabetes duration 1 year, which ensured adequate monitoring and treatment prior to baseline. Unfortunately, it is not possible to adjust for different intensity in antihypertensive treatment. The ideal situation would be to compare patients with low blood pressure due to intense treatment with patients with the same blood pressure but with low intensity treatment. This is, however, not possible due to confounding by indication for the drugs. We show in our study that treatment with several specific drugs is associated with a worse prognosis. Drugs such as β-blockers, loop-diuretics, spironolactone and thiazides are clearly used for other indications than hypertension. Hence, an important observation from our study is that prescription data can be used as a tool to adjust for comorbidity in observational studies. As discussed in our previous comment, we do not know for certain whether the observed blood pressure is due to treatment, concomitant disease or any other confounding factor. This is why we are only able to draw conclusions about the risk of having a certain blood pressure level, in contrast to being treated to a certain blood pressure level. In Sweden, the recommended blood pressure target in diabetes follow international guidelines and was unchanged between 1999 and It is possible that treatment intensity changed over time for each patient. These changes are often driven by risk factors and thus confounded by these. The only way to adjust for this would be marginal structural models, which would make the analysis very complex and difficult to interpret. This method also requires regular visits with complete data which is not the nature of our data. Our study design with long-term follow-up after careful baseline characterization of the patients is simple and straightforward. There are, however, certain limitations with this design which we have already declared in the discussion section, page 17: A decline in blood pressure during follow-up can be caused by comorbidity, changes in treatment or lifestyle, or a disease that is not easy to control for. Relying on a single measurement is likely to introduce a regression dilution effect due to the variability in blood pressure over time. This might lead to an attenuation of the relationship between blood pressure and outcome. We are not sure you can safely make claims about treatment guidelines. All we can safely observe is the effect of BP at one point in time. We cannot assume that a BP level at baseline is the
5 5 same as the goal BP level. We have concerns that you address the hypothesis but do not fulfil your aim. Reply: We agree that we cannot make claims about treatment guidelines, as discussed in our previous comments. But the current guidelines, both the European and from the American Diabetes Association (ADA), are derived from studies on non-diabetic patients, inconclusive trials, several observational studies and some, partly overlapping, meta-analyses of all these data. We therefore feel that there is an urgent need to provide new data to the ongoing discussion. We believe that our data are specifically relevant as it covers almost a whole nation and is obtained from day-to-day clinical practice. In the absence of large controlled trials in diabetes, all available information should be used to create a consensus about what to recommend. In the absence of new trials in diabetes, we have seen that the 2016 European guidelines (Piepoli et al European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J May ) have changed slightly, recommending systolic blood pressure in type 2 diabetes to be less than 130 mm Hg in selected patients which might be quite confusing to the practicing physician when the blood pressure target was raised to <140 mm Hg just a few years ago. In the introduction section, pages 6-7 we state that our hypothesis is that the J-curve phenomenon is due to concomitant comorbidities We also state that The aim of the study was to compare the risk associated with a systolic blood pressure that meets current recommendations with the risk of lower levels in patients who have type 2 diabetes and no previous cardiovascular disease. In our opinion, we have gone farther than previous studies in adjusting for comorbidity by: Examining a large number of patients from a nationwide diabetes register including only patients with diabetes duration 1 year excluding the oldest patients excluding individuals with previous major disease using drug prescription data as markers for comorbidity adjusting for other potential confounding factors using validated nationwide registers as endpoint sources We hereby believe that we have been able to show that: Lower systolic blood pressure than currently recommended is associated with significantly lower risk of cardiovascular events in patients with type 2 diabetes with no previous cardiovascular disease. Adjustment for comorbidity, mainly by excluding patients with previous cardiovascular disease, eliminates the J-curve relationship between blood pressure and stroke, myocardial infarction and coronary heart disease. How many patients were in the NDR database but without available BP levels? Reply: In total, individuals with type 2 diabetes were included in the NDR between 2006 and Of those, individuals (2.9%) were missing information on systolic or diastolic blood pressure. Could baseline BP be treated as a continuous variable? Reply: Yes, it would be possible to treat baseline blood pressure as a continuous variable but it is also clear that a simple linear model with proportional hazards would not fit the data very well. This could be avoided by the use of spline functions but by doing that, it would become much harder to
6 6 communicate the results. Furthermore, the reported blood pressures are often rounded to the nearest 5 or 10 mmhg, so the data may not be truly continuous. The predefined objective of our study was to compare the risk between different levels of blood pressure, mainly focusing on the old and new guideline targets (<130 mmhg vs <140 mmhg). We agree that it would be interesting to also estimate the optimal blood pressure, but we think that this research question would require a large amount of additional analyses, and would therefore be suitable for a separate article. Page 12. The causes of death in the various BP groups appear in the Supplement need to add Table S3. Reply: This has been corrected. Next paragraph should refer to _nonfatal_ CVD. Reply: This has been corrected.
7 7 Comments from the external peer reviewers Reviewer: 1 This looks like a well balanced review. The authors have excluded people with previous heart conditions, so the relationship between blood pressure and death in Type 2 diabetics seems to be measured more accurately This paper gives useful information which can guide short-term treatment guidelines Reply: Thank you for your appreciation of our study!
8 8 Reviewer: 2 Comments: This is an excellent and clearly written paper. It is original and makes a significant and highly clinically relevant new contribution to the literature on lower blood pressure levels and CVD risk in diabetics. There remains significant controversy about the possibility of a J-shaped relationship between BP and CVD which has impacted on international guideline recommendations on blood pressure lowering treatment goals and this study is by far the largest investigation ever done on the topic. The study is observational rather than an RCT and the authors are appropriately cautious about drawing conclusions about treatment based on a non-randomised study. However the authors are able to undertake analyses with appropriate exclusions that no other study has been big enough to allow and the sensitivity analyses including and excluding people with prior CVD provides compelling, albeit indirect evidence that the apparent J-shaped association between BP and CVD risk is an artifact due to reverse causality. The study is hard to fault and from the text and the references it is clear that the authors have a lot of experience in analysing (and publishing) these large-scale linked national datasets. One issue, I would like the authors to comment on is the possibility of a competing risk, which I couldn't find any mention of in the Discussion. The group with the lowest blood pressure had the highest total mortality so those who died of non-cvd causes (the majority of deaths) were not available to have a CVD event. I am sure the authors have considered this issue and I may have missed it. If not, could the authors please discuss this. Reply: Our answer to this comment is given under the committees comments. I note that the authors chose not to exclude those on loop diuretics and other drugs commonly used in the management of CVD. I would probably have excluded them, but the authors have adjusted for these groups in the analyses. I am not suggesting they re-do the analyses, which would be a huge undertaking, and the authors comment on this issue in the Discussion section. My guess is that the J-shaped relationship with BP and CHF might disappear if they had been excluded. Reply: Excluding patients on loop diuretics from the analysis gives almost identical results as adjustment for loop diuretics statistically. However, we have shown that spironolactone and other more common antihypertensive drugs (β-blockers, thiazide-diuretics, calcium antagonists and cardiovascular drugs that cannot be classified as antihypertensive drugs) are also associated with an increased cardiovascular risk. An explanation for β-blockers for example, is that both heart failure and angina are potential indications for treatment apart from hypertension. Patients who are treated with all these common agents cannot be excluded. We have shown that, from a methodological point of view, medications should instead be used as covariates. We are not aware of previous studies that have used this important information for adjustment for comorbidity. One minor issue, the mean SBP in each of the BP categories are skewed to the lower end of the range. For example the mmHg mean is 113mmHg. This is because GPs round the BP measurement. We have published data showing GPs tend to round SBP levels to the nearest 10mmHg which would account for this finding. It would be worth mentioning this issue in the text
9 9 because I am sure the true mean SBP in each category is closer to the middle value than is reported. Reply: Thank you for your valuable comment! We agree that the explanation to the observed skewness is due to rounding to the nearest 10 mmhg. This digit preference have previously been described in other Swedish primary care cohorts. (Qvarnstrom M, Wettermark B, Ljungman C, Zarrinkoub R, Hasselstrom J, Manhem K, et al. Antihypertensive treatment and control in a large primary care population of patients. J Hum Hypertens 2011; 25: Hasselstrom J, Zarrinkoub R, Holmquist C, Hjerpe P, Ljungman C, Qvarnstrom M, et al. The Swedish Primary Care Cardiovascular Database (SPCCD): hypertensive primary care patients. Blood Press 2014; 23: ) We have added comments on this in the result section, page 12, and in the discussion section, page 17.
10 10 Reviewer: 3 Comments: This very important paper describes the relationships between baseline BP and the subsequent risk of a range of important CV outcomes in people with diabetes. It is particularly important as this population has been the subject of substantial debate, with many people suggesting that BP lowering to below current targets may be harmful. These comments have been based on observational studies, including those from the registry used for this paper, which are prone to confounding and are therefore of uncertain reliability. The present analysis included a very large number of participants, allowing the authors to exclude those with previous CV disease, who are much more common at lower BP levels and are the likely source of residual confounding. When this was done, the relationship between BP and outcomes became linear for the vast majority of outcomes assessed, providing strong evidence in support of the likelihood of previous J-curve relationships being due to residual confounding, and the concept that BP levels below 120 are likely to be beneficial. There were only 2 outcomes for which a linear relationship was not clearly observed after excluding these individuals (heart failure and total mortality) but even these relationships were substantially attenuated after excluding existing CV disease, suggesting further unmeasured confounding is contributing. Furthermore, the apparently higher rates of death in the lowest BP group were due to factors that it is difficult to relate to BP lowering, and this population had the lowest doses of BP drugs. Taken together, these results strongly support BP lowering below current targets in diabetes, and are consistent with the existing but underpowered randomised trials. I think the description of previous studies in the discussion section could be shortened and the results summarised more succinctly. I also think it would be of interest to examine the relationship between BP levels and renal events if this is available. Reply: Thank you for your appreciation of our study and for your valuable comments! We believe that the detailed discussion on previous studies is of importance since we, point by point, try to explain why many of these studies, in our opinion, have been granted much weight when writing the guidelines. We agree that it would be interesting to examine the relationship between blood pressure levels and renal events. However, as this question was not included in our pre-defined objectives, we do not have access to the required data to perform these analyses for the moment. We estimate that it would take too much time to construct additional datasets to be able to add this question to the revised manuscript. We believe that this question instead may be suitable for a future follow-up study. Finally, studies showing an increased CV risk at lower BP levels have been published and promoted widely given their controversial nature. This higher quality and therefore more important study deserves the same airtime. Reply: Thank you for this comment!
Please revise your paper to respond to all of the comments by the reviewers. Their reports are available at the end of this letter, below.
Dear editor and dear reviewers Thank you very much for the additional comments and suggestions. We have modified the manuscript according to the comments below. We have also updated the literature search
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationBMJ - Decision on Manuscript ID BMJ
BMJ - Decision on Manuscript ID BMJ.2018.043414 Body: 19-Feb-2018 Dear Mr. Lee Manuscript ID BMJ.2018.043414 entitled "Predicted lean body mass, fat mass, and all-cause and cause-specific mortality in
More informationManuscript ID BMJ entitled "Benzodiazepines and the Risk of Allcause Mortality in Adults: A Cohort Study"
12-Jan-2017 Dear Dr. Patorno Manuscript ID BMJ.2016.036319 entitled "Benzodiazepines and the Risk of Allcause Mortality in Adults: A Cohort Study" Thank you for sending us your paper. We sent it for external
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationReviewer s report. Version: 0 Date: 17 Dec Reviewer: Julia Marcus. Reviewer's report:
Reviewer s report Title: Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with human immunodeficiency virus (HIV)?: a cohort collaboration
More informationID BMJ R4
Neeltje M Batelaan, MD PhD Department of Psychiatry, VU University Medical Center AJ Ernststraat 1187 1081 HL Amsterdam, the Netherlands Telephone +31-207885795 Email n.batelaan@ggzingeest.nl Re: Manuscript
More informationTitle:Impact of yoga on blood pressure and quality of life in patients with hypertension - a matched controlled trial in primary care
Author's response to reviews Title:Impact of yoga on blood pressure and quality of life in patients with hypertension - a matched controlled trial in primary care Authors: Moa Wolff (moa.wolff@med.lu.se)
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationDear Dr. Villanueva,
22-12-2017 Dear Dr. Villanueva, We would like to thank you for your interest in our paper and the opportunity to resubmit our manuscript Living network meta-analysis for reducing research waste: an empirical
More informationTitle: Survival endpoints in colorectal cancer. The effect of second primary other cancer on disease free survival.
Author's response to reviews Title: Survival endpoints in colorectal cancer. The effect of second primary other cancer on disease free survival. Authors: Helgi Birgisson (helgi.birgisson@surgsci.uu.se)
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationTitle:Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study
Author's response to reviews Title:Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study Authors: Anne Stine Kvehaugen (akvehaugen@yahoo.no)
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationMJ - Decision on Manuscript ID BMJ
MJ - Decision on Manuscript ID BMJ.2018.044966 Body: 12-Jul-2018 Dear Dr. Khandwala Manuscript ID BMJ.2018.044966 entitled "The Association of Paternal Age and Perinatal Outcomes between 2007 and 2016
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationAuthor's response to reviews
Author's response to reviews Title: Diabetes duration and health-related quality of life in individuals with onset of diabetes in the age group 15-34 years - a Swedish population-based study using EQ-5D
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationTitle:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.
Author's response to reviews Title:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Authors: Helen Cavanagh (helen21987@hotmail.com) Katherine MA Rogers (k.rogers@qub.ac.uk)
More informationTitle:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey
Author's response to reviews Title:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey Authors: Anne Helen Hansen
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationManuscript ID BMJ R1 entitled "Education and coronary heart disease: a Mendelian randomization study"
BMJ - Decision on Manuscript ID BMJ.2017.03 7504.R1 Body: 11-May-2017 Dear Dr. Tillmann Manuscript ID BMJ.2017.037504.R1 entitled "Education and coronary heart disease: a Mendelian randomization study"
More informationTitle: Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants
Author's response to reviews Title: Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants Authors: Simon Rueckinger (simon.rueckinger@med.uni-muenchen.de)
More informationDisclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012
How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D.,
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationType of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients Milne R J, Hoorn S V, Jackson R T Record
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationNurse-sensitive factors in hypertension management
Nurse-sensitive factors in hypertension management Hypertension treatment State of the Art Copper Hall 14:45-15:04 02/04/2011 Philippe van de Borne, MD, PhD Department of cardiology ULB-Erasme Hospital
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationBMJ - Decision on Manuscript ID BMJ
BMJ - Decision on Manuscript ID BMJ.2017.040049 Body: 14-Sep-2017 Dear Dr. Jaja Manuscript ID BMJ.2017.040049 entitled "Development and external validation of outcome prediction models for aneurysmal subarachnoid
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationBlood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study
OPEN ACCESS Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study Samuel Adamsson Eryd, 1,2,3 Soffia Gudbjörnsdottir,
More informationAuthor s response to reviews
Author s response to reviews Title: Effectiveness of Schroth exercises during bracing in adolescent idiopathic scoliosis: results from a preliminary study - SOSORT Award 2017 Winner Authors: Kenny Kwan
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationTitle:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke
Author's response to reviews Title:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke Authors: Kashif W Faiz (kashif.faiz@medisin.uio.no) Bente Thommessen (bente.thommessen@ahus.no)
More informationC. Data & methodology: validity of approach, quality of data, quality of presentation Excellent.
Reviewers' comments: Reviewer #1 (Immunotherapy expert) (Remarks to the Author): A. Summary of the key results This study elegantly demonstrates the sequential effects of bevacizumab followed by bevacizumab
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationAmbulatory blood pressure monitoring is key to improving hypertension diagnosis
Earn 2 CEU Points online Ambulatory blood pressure monitoring is key to improving hypertension diagnosis Professor Bryan Williams Director of the UCL Biomedical Research Centre University College London
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None How low should we go to avoid harm in hypertensives with comorbidities? CORONARY ARTERY DISEASE Prof. Dr. Maria DOROBANTU, FESC,FACC CARDIOLOGY EMERGENCY HOSPITAL
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPlease don't hesitate to contact me if you wish to discuss this further.
BMJ - Decision on Manuscript ID BMJ.2016.034988 Body: 11-Oct-2016 Dear Dr. Bell # BMJ.2016.034988 entitled "Association of clinically recorded alcohol consumption with the initial presentation of twelve
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationTitle: Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.
Author's response to reviews Title: Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. Authors: Mattias Neyt (mattias.neyt@kce.fgov.be) Stephan
More informationTitle: Selection effects may account for better outcomes of the German Disease Management Program for type 2 diabetes
Author's response to reviews Title: Selection effects may account for better outcomes of the German Disease Management Program for type 2 diabetes Authors: Ingmar Schäfer (in.schaefer@uke.uni-hamburg.de)
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationMaking comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups
Making comparisons Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups Data can be interpreted using the following fundamental
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Randi Selmer Senior Researcher Norwegian Institute of Public Health Norway
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationTitle:Video-confidence: a qualitative exploration of videoconferencing for psychiatric emergencies
Author's response to reviews Title:Video-confidence: a qualitative exploration of videoconferencing for psychiatric emergencies Authors: Marianne V Trondsen (marianne.trondsen@telemed.no) Stein Roald Bolle
More informationDRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials
DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationEPI 200C Final, June 4 th, 2009 This exam includes 24 questions.
Greenland/Arah, Epi 200C Sp 2000 1 of 6 EPI 200C Final, June 4 th, 2009 This exam includes 24 questions. INSTRUCTIONS: Write all answers on the answer sheets supplied; PRINT YOUR NAME and STUDENT ID NUMBER
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationAuthor's response to reviews
Author's response to reviews Title: Gender differences in Greek centenarians. A cross-sectional nation-wide study, examining multiple socio-demographic and personality factors and health locus of control.
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Ball State University
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More information논문투고및투고후소통하기 : 영문교정작업, 실제논문투고하기, revision 답변달기, query form 작성하기
Apr 28, 2018 9:20-9:40 JGO Workshop 논문투고및투고후소통하기 : 영문교정작업, 실제논문투고하기, revision 답변달기, query form 작성하기 연세의대이정윤 좋은아이디어를얻기위하여, 타인으로부터유익한암시를받을때가있음. 새로운아이디어는두사람이상의지식및아이디어를함께모을때생겨나는경우가있음. 토론은잘못의발견에유익한방법임. 혼자독립하여동료와이야기를나누지않는연구자는틀린길을걸어가다많은시간을낭비하게되는경우가있음.
More information